https://allsci.com/news/public-offerings/spyre-therapeutics-prices-usd-350m-offering-to/ AllScien 2026-10-06T13:34:53.731179Z Spyre raises USD 350m to advance immunology pipeline following Phase II readouts https://allsci.com/news/biotech/lycia-therapeutics-ipo-files-for-with-lytac/ AllScien 2026-10-06T13:26:18.732972Z Lycia Therapeutics files for IPO with LYTAC platform and Phase I food allergy data https://allsci.com/news/biotech/chronic-sciatica-consano-bio-secures-usd-15m-to/ AllScien 2026-10-06T12:07:26.330544Z Consano Bio raises over USD 15m to advance platelet-derived sciatica therapy https://allsci.com/news/clinical-trials/prv111-patch-clears-lesions-in-21-of-22-patients/ AllScien 2026-10-06T12:06:44.352083Z Privo’s cisplatin patch shows potential to spare oral cancer surgery https://allsci.com/news/clinical-trials/breast-cancer-trial-mrd-guided-strategy-in-early/ AllScien 2026-10-06T11:58:53.546761Z AFT, Natera launch Phase III to test MRD-guided deferral of CDK4/6 therapy in early breast cancer https://allsci.com/news/clinical-trials/odm-216-trial-orion-pharma-enters-clinical-stage/ AllScien 2026-10-06T11:38:52.362536Z Orion takes first biologic into clinical testing with PVRIG/PD-L1 bispecific https://allsci.com/news/clinical-trials/asthma-study-vial-doses-first-patient-in-phase-ib/ AllScien 2026-10-06T11:21:35.778299Z Vial starts Phase Ib asthma trial of IL-13 x TSLP bispecific targeting twice-yearly dosing https://allsci.com/news/biotech/eq504-trial-equillium-wins-australian-clearance/ AllScien 2026-10-06T11:10:05.727015Z Equillium cleared to start Phase I trial of oral AhR modulator EQ504 https://allsci.com/news/biotech/newly-diagnosed-dlbcl-epcoritamab-plus-r-chop/ AllScien 2026-10-06T09:50:28.659246Z Genmab, AbbVie report 51% reduction in progression or death with frontline epcoritamab https://allsci.com/news/ipo-public-listing/trex-bio-ipo-targets-usd-125m-to-advance-treg/ AllScien 2026-10-06T09:19:38.446944Z TRexBio targets up to USD 133m in Nasdaq IPO https://allsci.com/news/licensing-and-partnerships/gate-bioscience-expands-lilly-deal-to-unlock/ AllScien 2026-10-06T09:14:26.244782Z Lilly expands Gate Bioscience partnership with potential USD 870m deal https://allsci.com/news/biotech/rougetx-funding-raises-usd-58m-series-a-to-push/ AllScien 2026-10-06T08:44:13.871554Z Leiden Uni spinout RougeTx launches with USD 58m Series A for HHT program https://allsci.com/news/biotech/hdac-drug-discovery-italfarmaco-and-verisim-life/ AllScien 2026-10-05T16:29:46.599360Z Italfarmaco and VeriSIM Life combine AI and HDAC expertise in USD 100m+ drug discovery deal https://allsci.com/news/m-a/shionogi-intrabio-acquisition-acquires-for-usd-2b/ AllScien 2026-10-05T16:28:16.302376Z Shionogi pays USD 2bn for IntraBio and two-indication rare disease drug Aqneursa https://allsci.com/news/clinical-trials/vax-31-results-meets-all-primary-endpoints-in/ AllScien 2026-10-05T16:16:06.221198Z Vaxcyte’s VAX-31 clears pivotal Phase III against Prevnar 20 and Capvaxive https://allsci.com/news/biotech/sernova-financing-and-seraxis-close-usd-112m-to/ AllScien 2026-10-05T16:15:22.377232Z Sernova and Seraxis close USD 11.2m financing to advance merger and T1D cell therapy trial https://allsci.com/news/biotech/2026-nobel-prize-karolinska-institutet-awards-in/ AllScien 2026-10-05T13:58:27.943230Z 2026 Nobel medicine prize honors Deisseroth, Hegemann and Nagel for optogenetics https://allsci.com/news/biotech/parkinsons-gcase-therapy-alector-secures-usd-100m/ AllScien 2026-10-05T13:52:06.690798Z Alector secures USD 100m upfront from Genentech for brain-penetrant GCase therapy in Parkinson's disease https://allsci.com/news/research/tauopathy-treatment-washu-researchers-show/ AllScien 2026-10-05T13:22:38.000599Z WashU researchers show blocking T-cell brain entry protects against tau-driven damage in mice https://allsci.com/news/licensing-and-partnerships/sleep-disorder-drug-nhwa-licenses-to-somnivera/ AllScien 2026-10-05T13:13:53.726725Z Nhwa licenses sleep-disorder drug to Somnivera for up to USD 517.5m outside Greater China https://allsci.com/news/clinical-trials/dmd-treatment-ractigens-rag-18-triggers-utrophin/ AllScien 2026-10-05T12:32:42.385156Z Ractigen’s RAG-18 triggers utrophin upregulation in first-in-human DMD data https://allsci.com/news/biotech/platinum-resistant-ovarian-cancer-rina-s-delivers/ AllScien 2026-10-05T12:29:03.434035Z Rina-S delivers 46% response rate and 12-month durability in platinum-resistant ovarian cancer https://allsci.com/news/approvals/jaypirca-cll-approval-fda-expands-into-first-line/ AllScien 2026-10-05T12:12:14.675348Z Jaypirca breaks into first-line CLL/SLL with FDA approval https://allsci.com/news/licensing-and-partnerships/hunter-syndrome-italfarmaco-licenses-jcrs/ AllScien 2026-10-05T11:16:51.579041Z Italfarmaco licenses JCR's brain-penetrating Hunter syndrome therapy for US, Europe and Latin America https://allsci.com/news/biotech/pompe-disease-five-year-propel-data-show/ AllScien 2026-10-05T11:08:30.251262Z BioMarin reports durable five-year outcomes with Pombiliti/Opfolda in late-onset Pompe disease https://allsci.com/news/cancer-death-rates-cdc-nci-acs-and-naaccr-report/ AllScien 2026-10-05T10:12:25.611763Z Annual US cancer report finds lung cancer gains driving two-decade decline in deaths https://allsci.com/news/research/cdk46-inhibitor-resistance-boston-childrens/ AllScien 2026-10-05T10:08:41.253941Z Boston Children’s researchers uncover nuclear FAH role in CDK4/6-resistant breast cancer https://allsci.com/news/licensing-and-partnerships/lixudebart-deal-csl-bets-usd-355m-upfront-on/ AllScien 2026-10-05T09:54:59.449315Z CSL bets USD 355m upfront on Alentis' claudin-1 antibody lixudebart in rare kidney and liver diseases https://allsci.com/news/biotech/celaid-therapeutics-secures-jpy-400m-second-close/ AllScien 2026-10-05T09:53:45.784718Z Japan's Celaid raises JPY 400m as lead stem-cell therapy heads towards US trial https://allsci.com/news/biotech/denecimig-approval-fda-manufacturing-review/ AllScien 2026-10-05T09:43:50.804187Z US FDA delays review of Novo hemophilia drug denecimig over manufacturing issue https://allsci.com/news/biotech/sbma-treatment-annji-advances-aj201-into-phase/ AllScien 2026-10-05T09:24:34.428944Z AnnJi advances androgen receptor-clearing rosolutamide into Phase III for Kennedy’s disease https://allsci.com/news/biotech/tre-515-fast-track-fda-grants-designation-kras/ AllScien 2026-10-05T08:59:51.897575Z Trethera wins Fast Track for dCK inhibitor TRE-515 in KRAS G12C lung cancer combination https://allsci.com/news/clinical-trials/cutaneous-lupus-biogens-litifilimab-shows/ AllScien 2026-10-05T08:21:32.038745Z Biogen’s litifilimab builds momentum with durable 52-week responses in CLE